Insulin-like growth factor 1 (IGF-1)
IGF1 encodes insulin-like growth factor 1, a peptide growth factor with central roles in postnatal growth, tissue repair, metabolism, and endocrine signaling.
IGF1 encodes insulin-like growth factor 1, a peptide growth factor with central roles in postnatal growth, tissue repair, metabolism, and endocrine signaling. It is a key mediator of growth hormone (GH) action and is widely used as a circulating biomarker of growth axis activity. In physiology, IGF-1 supports skeletal growth, muscle maintenance, and anabolic processes, while also participating in broader pathways linked to insulin sensitivity, inflammation, and aging.
Clinically, IGF-1 is relevant across multiple disease areas, including short stature, acromegaly, haemophilic arthropathy, osteoarthritis, breast cancer, type 2 diabetes, and age-related musculoskeletal decline. Because IGF-1 reflects both endocrine status and local tissue biology, it is frequently studied as a biomarker, a mechanistic mediator, and a target within pathway-based analyses involving growth hormone (GH), IGFBP-3, signal transducer and activator of transcription 3 (STAT3), Phosphatidylinositol 3-kinase (PI3K), vascular endothelial growth factor A (VEGFA), Leptin (LEP), and related signaling networks.
Where the papers sit
11 papers from the last 6 months study Insulin-like growth factor 1 (IGF-1) directly · updated from PubMed 4 Oct 2026
Study type 0 clinical trials · 5 observational · 6 preclinical
Themes 3 themes · 1 new direction
-
Growth Hormone and IGF-1
Growth assessment is moving toward combined GH–IGF-1 interpretation rather than isolated measurements. Height and assay relationships, postoperative biochemical discordance in acromegaly, and environmental enteric dysfunction frame IGF-1 as a context-dependent growth marker. Juvenile vaccine exposure and nutrition-related growth impairment broaden the search for modifiers, while animal studies test IGF-1 against ferroptosis-driven cardiomyopathy and muscle injury. The evidence remains heterogeneous, with no single clinical intervention emerging.
6 papers · 54.5%
-
IGF-1 Disease Associations
IGF-1 is examined across gastric cancer signaling, multi-constituent herbal therapy, and haemophilic arthropathy biomarkers. Quercetin work prioritizes IGF1 pathway targets using network pharmacology, molecular docking, and AGS-cell assays, while Yinxingye Tablets is mapped by UPLC-QTOF-MS. uCTX-II, CS846, and IGF-1 track clinical and ultrasound severity in haemophilic arthropathy. These strands share IGF-1 as a candidate mechanism or marker but establish no common therapeutic direction.
3 papers · 27.3%
-
IGF Signaling in Breast Cancer
Breast cancer research is linking the IGF-1/IGFBP-3 axis to ER, progesterone receptor, and HER2-defined subtypes. Serum levels and IGFBP3 polymorphisms are being evaluated for subtype-associated biomarker value. Parallel treatment work combines CDK4/6 inhibition with CSF1R blockade to counter immunosuppression and strengthen antitumor immunity in HR+/HER2- disease. Molecular stratification and combination therapy are gaining emphasis, but the predictive value of IGF-axis measurements remains unresolved.
2 papers · 18.2%
In HR+/HER2− breast cancer, IGF-1 is identified as a therapy-induced stromal driver of immune suppression
In HR+/HER2− breast cancer treated with the CDK4/6 inhibitor palbociclib, the study found that drug-induced fibroblast senescence increased IGF-1 and FGF7, which drove macrophages toward an M2-like phenotype through STAT3 phosphorylation and ARG1 upregulation, depleting arginine and reducing lymphocyte viability; this assigns IGF-1 a paracrine role in remodeling the tumor immune microenvironment rather than the biomarker, growth-related, or tumor-target roles represented elsewhere in the set, and points to stromal IGF-1 signaling as a mechanism of treatment-associated immunosuppression that can be therapeutically countered with CSF1R inhibition 41986650Apr.
Papers
The 11 papers from the last 6 months that study Insulin-like growth factor 1 (IGF-1) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Growth Hormone and IGF-1 (6)
- Prevalence and patterns of biochemical discordance in patients with surgically treated acromegaly. Pituitary · 23 May 2026 PMID 42177388
- The correlation between height and assay parameters in children with short stature. Medicine · 23 May 2026 PMID 42175428
- Environmental enteric dysfunction influences linear growth of children through insulin-like growth factor-1: findings from the Indonesian Action Against Stunting Hub birth cohort. Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 14 May 2026 PMID 42132033
- Impaired growth after immunization with a bivalent oil-adjuvanted vaccine occurs without detectable changes to aerobic capacity in juvenile rainbow trout. Comparative biochemistry and physiology. Part A, Molecular & integrative physiology · 12 May 2026 PMID 42119917
- Evaluation of the effects of ivermectin and Moringa oleifera nanoparticles on muscular trichinellosis in a murine model. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 26 Apr 2026 PMID 42035901
- IGF-1 attenuates high fat diet-elicited cardiomyopathy via arachidylcarnitine-dependent suppression of ferroptosis and mitochondrial dysfunction. European journal of pharmacology · 16 Apr 2026 PMID 41990905
IGF-1 Disease Associations (3)
- Quercetin targets IGF1 signaling in gastric cancer: a synergy of network pharmacology, molecular simulations, and in vitro functional assays. Journal of computer-aided molecular design · 15 Jun 2026 PMID 42295420
- The biomarkers uCTX-II, CS846 and IGF-1 are associated with clinical and ultrasound scores in haemophilic arthropathy: a cross-sectional study. Rheumatology international · 30 May 2026 PMID 42217051
- Integrated UPLC-QTOF-MS and Network Pharmacology for Predicting Active Constituents and Pharmacological Mechanisms of Yinxingye Tablets Against Oxidative Stress. Biomedical chromatography : BMC · 9 May 2026 PMID 42104588
IGF Signaling in Breast Cancer (2)
- Interplay of the IGFBP-3 polymorphism and serum levels of IGF-1/IGFBP-3 with hormone receptor subtypes in patients with breast cancer among Palestinian women. PloS one · 1 Jun 2026 PMID 42224209
- CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer. Oncogene · 15 Apr 2026 PMID 41986650
By study type
Observational studies and case reports (5)
- Interplay of the IGFBP-3 polymorphism and serum levels of IGF-1/IGFBP-3 with hormone receptor subtypes in patients with breast cancer among Palestinian women. PloS one · 1 Jun 2026 PMID 42224209
- The biomarkers uCTX-II, CS846 and IGF-1 are associated with clinical and ultrasound scores in haemophilic arthropathy: a cross-sectional study. Rheumatology international · 30 May 2026 PMID 42217051
- Prevalence and patterns of biochemical discordance in patients with surgically treated acromegaly. Pituitary · 23 May 2026 PMID 42177388
- The correlation between height and assay parameters in children with short stature. Medicine · 23 May 2026 PMID 42175428
- Environmental enteric dysfunction influences linear growth of children through insulin-like growth factor-1: findings from the Indonesian Action Against Stunting Hub birth cohort. Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 14 May 2026 PMID 42132033
Preclinical: animal, cell and lab studies (6)
- Quercetin targets IGF1 signaling in gastric cancer: a synergy of network pharmacology, molecular simulations, and in vitro functional assays. Journal of computer-aided molecular design · 15 Jun 2026 PMID 42295420
- Impaired growth after immunization with a bivalent oil-adjuvanted vaccine occurs without detectable changes to aerobic capacity in juvenile rainbow trout. Comparative biochemistry and physiology. Part A, Molecular & integrative physiology · 12 May 2026 PMID 42119917
- Integrated UPLC-QTOF-MS and Network Pharmacology for Predicting Active Constituents and Pharmacological Mechanisms of Yinxingye Tablets Against Oxidative Stress. Biomedical chromatography : BMC · 9 May 2026 PMID 42104588
- Evaluation of the effects of ivermectin and Moringa oleifera nanoparticles on muscular trichinellosis in a murine model. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 26 Apr 2026 PMID 42035901
- IGF-1 attenuates high fat diet-elicited cardiomyopathy via arachidylcarnitine-dependent suppression of ferroptosis and mitochondrial dysfunction. European journal of pharmacology · 16 Apr 2026 PMID 41990905
- CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2- breast cancer. Oncogene · 15 Apr 2026 PMID 41986650
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.